-
Science sub-journal: Developed a CAR combined screening method to determine the most effective CAR-T cells for cancer treatment
Time of Update: 2023-01-05
Now, in a new study, researchers from the University of California, San Francisco, have developed a new way to compare large numbers of CAR-T cells, each with slightly different molecular characteristics, to determine which CAR-T cells are most effective and durable against cancer 。 The results were published in the Nov. 9, 2022 issue of Science Translational Medicine as "Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies.
-
Cell Journal (IF=17) Zu Xiongbing's team at Central South University discovered a safe
Time of Update: 2022-11-01
Immune checkpoint blockade (ICB), including anti-PD-1/PD-L1, has shown promising survival benefits and revolutionized the status quo of treatment for patients with advanced MIBC.
Original link: #—END—content is 【iNature】 Immune checkpoint blockade (ICB), including anti-PD-1/PD-L1, has shown promising survival benefits and revolutionized the status quo of treatment for patients with advanced MIBC.
-
Cell sub-journal: Zu Xiongbing's team at Central South University discovered a safe and effective
Time of Update: 2022-10-25
OnOctober192022, the Zu Xiongbing team of Central South Universitypublished an online titleCell Reports Medicine(IF=17 Research paper "Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study", To parallelize neoadjuvant immunotherapytislelizumab(gemcitabine and cisplatin),and neoadjuvant combination therapy(tislelizumab+ GC)exploring predictors of efficacy, which conducted a multicenter, real-world cohort study that demonstrated the highest rates of complete response and pathologic de-staging compared with neoadjuvant immunotherapy or chemotherapy.
-
JAMA sub-journal: Neoadjuvant intensity-modulated radiotherapy combined with surgery is safe
Time of Update: 2022-10-20
(If you need the original text, you can add Xiaobian WeChat yxj_oncology to obtain) 1JAMA sub-journal: Neoadjuvant intensity-modulated radiotherapy combined with surgery is safe and effective in the treatment of central hepatocellular carcinoma▎Clinical problems:Central hepatocellular carcinoma (HCC) is a specific type of liver cancer that is not well treated with surgery alone, and there is currently no standard adjuvant or neoadjuvant therapy that can improve clinical outcomes.
-
in the international journal JAMA, and the positive results of H drug Hans-shaped (R) combined with chemotherapy
Time of Update: 2022-10-20
ASTRUM-005 study is a phase III clinical study of anti-PD-1 monoclonal antibody H drug independently developed by Henlius Hans-form ® (serplulimab) combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), after Professor Cheng Ying reported the results for the first time at the 2022 ASCO Annual Meeting, which attracted widespread attention from global peers, and now has once again appeared on the international top academic stage, reflecting the high recognition of the international academic community.
-
Nature Sub-Journal: EGFR/HER2 Dual Targeted PDC Combination for the Treatment of Pancreatic Cancer
Time of Update: 2022-10-14
:CN109954130,CN109957591)On September 20, the team published an article titled "An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated" in Nature Communications Mechanisms", which explains the efficacy of DTLL in combination with gemcitabine in vitro and explains its possible mechanism of action.
-
in the international top journal JAMA, H drug Hans-like combination chemotherapy first-line ® treatment of extensive small cell lung cancer positive results were released
Time of Update: 2022-10-13
On September 27, 2022, the international multicenter research led by Professor Cheng Ying, ASTRUM-005 research, one of the world's top four medical journals, Journal of the American Medical Associatio
-
Nature Sub-Journal: Combining artificial intelligence and brain electrical stimulation to improve human brain function
Time of Update: 2021-12-07
In this study, the research team combined artificial intelligence with targeted brain electrical stimulation, showing that precisely directed electrical stimulation can reliably enhance specific human mental functions related to mental illness, and that there are specific sub-capsules in the brain capsule structure.
-
[Science Sub-Journal] Cupping + new crown DNA vaccine = immune response × 100, Chinese scientists
Time of Update: 2021-11-13
Researchers at Rutgers University studying COVID-19 used a suction technique similar to ancient cupping to invent a new method of delivering DNA molecules to skin cells .
-
Lancet Sub-Journal: Ramucirumab combined with paclitaxel can be used as a second-line treatment
Time of Update: 2021-10-09
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial .
-
Nature Sub-Journal: Plasma phosphorylated tau combined with other methods can predict Alzheimer's disease
Time of Update: 2021-09-06
On May 24, 2021, Oskar Hansson, Sebastian Palmqvist and other researchers from Lund University in Sweden jointly published an online publication entitled "Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures" in the journal Nature Medicine.
-
Science Sub-Journal: To "escort" tumor immunotherapy, Chinese and American scientists release the latest cancer-blocking combination therapy
Time of Update: 2021-08-07
"preclinical models" research article, the study puts forward a new direction for escorting tumor immunotherapy-the delivery of PTEN mRNA into tumor cells through lipid polymer nanoparticles can effectively induce tumor cell autophagy and release damage-related patterns Molecules (damage-associated molecular patterns, DAMPs) trigger the activation of cell death-related immunity, thereby enhancing the efficacy of ICB therapy .
-
Science Sub-Journal: Combined use of low-dose radiotherapy and immunotherapy can eradicate metastatic cancer in mice
Time of Update: 2021-08-05
The relevant research results were published in the journal Science Translational Medicine on July 14, 2021, with the title of the paper "Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade" .
-
JAMA Sub-Journal: Is ticagrelor combined with "magic drug" aspirin more effective in the treatment of patients with stroke
Time of Update: 2021-07-27
StrokeBased on these studies, current guidelines recommend early and short-term (21 days) combined treatment of clopidogrel and aspirin for high-risk TIA and mild non-cardiac ischemic stroke patients with NIHSS scores of 3 or less .
-
Sub-Journal of The Lancet: Protecting β-cells in Type 1 Diabetes Patients, Liraglutide Combination Therapy Passed Proof-of-Concept International Research
Time of Update: 2021-03-24
Image source: 123RF Based on these findings, the research team believes that the combination of anti-IL-21 monoclonal antibody and liraglutide can preserve β-cell function in newly diagnosed type 1 diabetes patients.